[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100068977":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":16,"responsibleParty":7,"collaborators":7,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":7,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":7,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":7,"overallStatus":93,"whyStopped":7,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Pfizer","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","CP-526,555 (varenicline)",[13],{"name":14,"affiliation":5,"role":15},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[17,29,37,44,52,60,68],{"facility":18,"status":7,"city":19,"state":20,"zip":7,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":7},"Pfizer Investigational Site","Lexington","Kentucky","United States","US",{"type":24,"coordinates":25},"Point",[26,27],-84.47772,37.98869,{"lat":27,"lon":26},{"facility":18,"status":7,"city":30,"state":31,"zip":7,"country":21,"countryCode":22,"cosmosGeoPoint":32,"geoPoint":36,"contacts":7},"Albert Lea","Minnesota",{"type":24,"coordinates":33},[34,35],-93.36827,43.64801,{"lat":35,"lon":34},{"facility":18,"status":7,"city":38,"state":31,"zip":7,"country":21,"countryCode":22,"cosmosGeoPoint":39,"geoPoint":43,"contacts":7},"Rochester",{"type":24,"coordinates":40},[41,42],-92.4699,44.02163,{"lat":42,"lon":41},{"facility":18,"status":7,"city":45,"state":46,"zip":7,"country":21,"countryCode":22,"cosmosGeoPoint":47,"geoPoint":51,"contacts":7},"Philadelphia","Pennsylvania",{"type":24,"coordinates":48},[49,50],-75.16362,39.95238,{"lat":50,"lon":49},{"facility":18,"status":7,"city":53,"state":54,"zip":7,"country":21,"countryCode":22,"cosmosGeoPoint":55,"geoPoint":59,"contacts":7},"Providence","Rhode Island",{"type":24,"coordinates":56},[57,58],-71.41283,41.82399,{"lat":58,"lon":57},{"facility":18,"status":7,"city":61,"state":62,"zip":7,"country":21,"countryCode":22,"cosmosGeoPoint":63,"geoPoint":67,"contacts":7},"La Crosse","Wisconsin",{"type":24,"coordinates":64},[65,66],-91.23958,43.80136,{"lat":66,"lon":65},{"facility":18,"status":7,"city":69,"state":62,"zip":7,"country":21,"countryCode":22,"cosmosGeoPoint":70,"geoPoint":74,"contacts":7},"Madison",{"type":24,"coordinates":71},[72,73],-89.40123,43.07305,{"lat":73,"lon":72},"100068977","phase-2-12-week-evaluation-of-the-safety-and-efficacy-of-a-flexible-dose-of-cp-526555-and-placebo-for-smoking-cessation-100068977",false,"NCT00150228","12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation","A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation","Inclusion Criteria:\n\n* Subjects must have smoked an average of at least ten cigarettes per day during the past year\n* No period of abstinence greater than three months in the past year\n\nExclusion Criteria:\n\n* Subjects with history of clinically significant cardiovascular disease\n* Subjects with uncontrolled hypertension.","ALL","18 Years","65 Years",{"count":86,"type":7},300,"INTERVENTIONAL",[89],"PHASE2","The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019",[92],"Smoking Cessation","COMPLETED","2007-05-31",{"date":96,"type":97},"2007-06-04","ESTIMATED",{"date":99,"type":7},"2001-12",{"date":101,"type":102},"2002-09","ACTUAL",{"name":5,"class":6},7]